FDA CRL - Atara Biotherapeutics, Inc.

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Atara Biotherapeutics, Inc. on January 15, 2025, regarding its Biologics License Application for tabelecleucel. The agency was unable to grant final approval due to unresolved deficiencies concerning Chemistry, Manufacturing, and Controls.

Specifically, the FDA noted that corrections to observations made during a pre-license inspection of a manufacturing facility have not been adequately demonstrated and remain unresolved. These issues may necessitate further review, potentially including a follow-up inspection. As a result, the FDA's Center for Biologics Evaluation and Research (CBER) could not confirm that the product and establishment comply with the standards outlined in the BLA and FDA regulations, including current good manufacturing practice requirements, under 21 CFR 601.20(a) and (d).

Comments on the proposed labeling are reserved pending resolution of the other issues. Atara Biotherapeutics is required to either resubmit a complete response addressing all deficiencies or withdraw the application within one year. The company also has the option to request an extension or a meeting with the FDA to discuss the necessary steps for approval.